Financial Performance - The company's operating revenue for 2023 reached ¥5,700,286,745.90, representing an increase of 11.89% compared to the previous year[27]. - Net profit attributable to shareholders for 2023 was ¥1,119,142,042.33, marking a 29.05% increase year-over-year[27]. - The net profit after deducting non-recurring gains and losses was ¥1,003,471,054.23, up 24.77% from the previous year[27]. - Basic earnings per share for 2023 were ¥1.92, a 29.73% increase compared to ¥1.48 in 2022[27]. - The total assets at the end of 2023 were ¥6,881,912,554.92, a decrease of 2.13% from the previous year[27]. - Net assets attributable to shareholders increased by 13.29% to ¥4,763,440,300.18 at the end of 2023[27]. - The company reported total assets of 688,191.26 million CNY and net assets attributable to shareholders of 476,344.03 million CNY as of the end of 2023[67]. - The company reported a sales volume of 816,798,369 boxes in 2023, representing a year-on-year increase of 7.21% compared to 2022[105]. - The production volume for 2023 was 880,196,479 boxes, reflecting a significant year-on-year growth of 21.03%[105]. - The company's inventory increased dramatically by 234.37% year-on-year, reaching 90,449,002 boxes in 2023[105]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 15 RMB per 10 shares to all shareholders based on a total share capital of 584,000,000 shares as of December 31, 2023[16]. Strategic Focus and Market Position - The company aims to enhance its focus on traditional Chinese medicine, aligning with national policies to promote its development[35]. - The company aims to strengthen its leading position in the OTC market while increasing investment in advanced business models in the pharmaceutical and health sectors[59]. - The company is focused on expanding its market presence through both internal growth and external investments, aiming to unlock user, brand, channel, and investment value[58]. - The company is committed to enhancing its brand value and user experience through high-quality products and integrity in operations[61]. - The company is enhancing its product structure and adopting a proactive approach to research and development to capture emerging market segments[184]. Risks and Challenges - The company faces risks including market competition, raw material price fluctuations, and potential underperformance of new products[39]. - The company is addressing risks related to policy changes in the pharmaceutical industry, raw material price fluctuations, and new product introduction failures by enhancing internal controls and optimizing business structures[161][162]. - The company recognizes risks related to market competition and fluctuations in raw material prices, and it is actively monitoring these factors to mitigate potential impacts on profitability[183][184]. Research and Development - Research and development investment rose to 128,647,229.20 yuan in 2023, a 35.97% increase from 2022, accounting for 2.26% of operating revenue[113]. - The company is actively developing 36 functional food projects, emphasizing its commitment to health and wellness products[69]. - The company has a total of 1,126 drug approval numbers, with 555 included in the national medical insurance directory and 283 in the national essential drug list, indicating a strong product portfolio[87]. - The company is expanding its product pipeline through mergers, independent research and development, and partnerships, enhancing its competitive edge in the pharmaceutical market[87]. Operational Efficiency - The company aims to enhance operational efficiency and resource allocation through improved financial management and digitalization efforts[74]. - The company is focusing on cost control through strategic reserves and optimizing production processes to mitigate the impact of rising raw material prices[73]. - The company is committed to optimizing its total cost structure by selecting raw materials carefully and improving production processes to ensure cost efficiency[182]. Brand and Marketing Strategies - The company has implemented a new media communication strategy in 2023, enhancing brand exposure and customer engagement through various promotional activities[72]. - The company aims to enhance brand recognition and drive online growth through user-centric strategies and effective product management[145]. - The company is leveraging digitalization and AI to enhance its marketing strategies and drive growth in the traditional pharmaceutical industry[159]. Corporate Governance and Compliance - The company is committed to continuous improvement in corporate governance and compliance with regulatory requirements[167]. - The company emphasizes the importance of a robust compliance system and organizational development to support sustainable growth[182]. Community Engagement - The company has committed over 11 million yuan in social donations in 2023, including more than 8 million yuan in cash donations[122].

证券代码：002737 证券简称：葵花药业 公告编号：2024-012 葵花药业集团股份有限公司 关于会计政策变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）于 2024 年 4 月 25 日召开第四届董事会第二十九次会议和第四届监事会第二十二次会议， 审议通过了《关于会计政策变更的议案》，同意根据相关法律、法规及规范性文 件要求，执行新的会计政策。具体情况如下： 根据财政部相关准则及通知规定，上述事项自 2023 年 1 月 1 日起施行。 （二）变更前后采用的会计政策 1、变更前采用的会计政策 本次变更前，公司执行财政部发布的《企业会计准则—基本准则》及各项具 体会计准则、企业会计准则应用指南、企业会计准则解释公告及其他相关规定。 2、变更后采用的会计政策 本次会计政策变更后，公司将按照财政部发布的准则解释 16 号的要求执行。 除上述会计政策变更外，其他未变更部分，仍按照财政部前期颁布的《企业会计 1 一、本次会计政策变更概述 （一）会计政策变更的原因及变更日期 1、变更原因 2022 ...

Financial Performance - The company's operating revenue for the current period is ¥1,518,181,069.65, a decrease of 14.01% compared to the same period last year[6] - The net profit attributable to shareholders for the current period is ¥255,183,288.86, down 37.17% year-over-year[6] - The net profit after deducting non-recurring gains and losses is ¥237,454,340.04, reflecting a decline of 39.18% compared to the previous year[6] - The basic earnings per share for the current period is ¥0.44, a decrease of 37.14% from ¥0.70 in the same period last year[6] - The total operating revenue for the first quarter of 2024 was ¥1,518,181,069.65, a decrease of approximately 14.0% compared to ¥1,765,521,894.46 in the same period last year[26] - The net profit attributable to shareholders of the parent company was ¥255,206,220.86, down from ¥406,131,973.46, representing a decrease of about 37.1%[28] - The basic and diluted earnings per share for the first quarter were both ¥0.44, compared to ¥0.70 in the same period last year, a decline of approximately 37.1%[28] - Net profit decreased by 37.91% to ¥270,303,238.96 compared to ¥435,364,881.11 in the previous period, primarily due to a decline in revenue and increased costs from rising Chinese medicinal material prices[44] Assets and Equity - The total assets at the end of the current period amount to ¥7,146,595,311.44, representing a 3.85% increase from the end of the previous year[6] - The equity attributable to shareholders at the end of the current period is ¥5,021,155,795.83, which is a 5.41% increase compared to the previous year[6] - The total current assets increased to ¥5,087,394,714.11 from ¥4,787,964,197.21, reflecting an increase of approximately 6.3%[24] - The cash and cash equivalents at the end of the period were ¥3,496,677,467.15, up from ¥2,287,009,419.54, representing an increase of about 53.0%[24] - The inventory balance increased to ¥909,915,396.70 from ¥873,189,831.01, showing an increase of approximately 4.2%[24] - The total assets increased to ¥7,146,595,311.44 from ¥6,881,912,554.92, reflecting a growth in overall asset base[43] Cash Flow - The net increase in cash and cash equivalents for the current period is ¥1,209,972,261.26, compared to ¥451,842,275.99 in the previous year[3] - The cash flow from operating activities for the current period is ¥204,290,572.95, down 17.97% from the previous year[6] - The net cash flow from operating activities was ¥204,290,572.95, compared to ¥249,028,652.64 in the previous year, indicating a decline of approximately 17.9%[30] - Cash inflow from investment activities totaled ¥1,020,817,239.73, significantly higher than ¥252,569,927.27 in the previous year[30] - The cash outflow for purchasing fixed assets and intangible assets was ¥13,985,381.42, compared to ¥36,350,120.38 in the previous year, indicating a decrease of about 61.6%[30] - Investment activities generated a net cash flow of ¥1,006,831,858.31, a significant increase of 413.11% from ¥196,219,806.89 in the previous period, mainly due to the redemption of maturing financial products[44] - Cash and cash equivalents increased by 52.89% to ¥3,496,677,467.15 from ¥2,287,009,419.54, primarily due to the redemption of financial products during the period[50] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 32,355[52] - The largest shareholder, KuaHua Group Co., Ltd., holds 45.41% of the shares, totaling 265,200,000 shares[52] - The second-largest shareholder, Guan Yanbin, holds 6.03% of the shares, totaling 35,220,422 shares[52] - The company has not engaged in margin trading or securities lending activities by its controlling shareholders or related parties[52] Government Support and Other Income - The company received government subsidies amounting to ¥22,444,571.68 during the current period[18] - Other income rose by 42.22% to ¥23,156,203.91, primarily due to government subsidies received in the current period[44] Operational Developments - The company has made progress in product development, including the approval of a new oral suspension product[23] - The report indicates a focus on financial product management and revenue recognition strategies for future growth[50] - The company is exploring market expansion opportunities and potential mergers and acquisitions to enhance its competitive position[50] Financial Management - Financial expenses decreased by 99.69% to -¥11,113,152.12, attributed to an increase in bank interest income during the current period[44] - Credit impairment losses increased by 82.60% to -¥2,991,054.06, mainly due to provisions for bad debts[44] - The company reported a 272.37% increase in operating expenses to ¥938,184.74, primarily due to external donation expenditures[44] - The fair value change in investment income showed a significant increase of 98.35%, reaching ¥5,407,601.03, attributed to returns from financial products[44] - The cash flow from financing activities decreased by 115.39% to -¥1,015,792.56, primarily due to the absence of bank borrowings in the current period[44] Liabilities and Receivables - Trading financial assets decreased by 77.18% to ¥300,159,000.00 from ¥1,315,104,600.00, also attributed to the redemption of financial products[50] - Accounts receivable financing rose by 157.57% to ¥92,248,199.27 from ¥35,814,204.43, mainly due to an increase in collected notes[50] - Contract liabilities decreased by 47.21% to ¥156,972,360.41 from ¥297,324,795.11, primarily due to revenue recognition based on performance obligations[50]

1、董事会、股东大会 | | | | 出席董事会情况 | | | 列席股东大会情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 施先旺 | 应参加 董事会 | 亲自出 | 委托出 | 缺席次 | 是否连续两 次未出席会 | 股东大会 | 列席次 | | | | 席次数 | 席次数 | 数 | | 次数 | 数 | | | 次数 | | | | 议 | | | | | 5 | 4 | 1 | 0 | 否 | 2 | 1 | 葵花药业集团股份有限公司 2023 年度独立董事述职报告 本人施先旺，作为葵花药业集团股份有限公司（以下简称"公司"或"本公 司"）的独立董事，任职期间严格按照《公司法》、《上市公司治理准则》、《上 市公司独立董事管理办法》、《公司章程》等相关法律法规和规章制度的规定和 要求，谨慎、认真地行使独立董事的各项权利，忠实、勤勉地履行独立董事职责 和义务，忠诚维护公司整体利益和全体股东特别是中小股东的合法权益。 现将 2023 年度本人履职情况报告如下： 一、 出席会议情况 本人出席会议情况如下： （施先旺） 报告期内，本人针对公 ...

证券代码：002737 证券简称：葵花药业 公告编号：2024-011 葵花药业集团股份有限公司 三、备查文件 关于 2024 年度向银行申请综合授信额度的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、基本情况 为保证公司整体发展战略规划的实施，推动公司综合竞争力的提升，在确保 运作合规和风险可控的前提下，公司(含纳入公司合并报表范围的下属子公司) 2024 年度拟向银行申请综合授信额度，具体情况如下： 1、拟申请额度：不超过人民币 20 亿元 (含前期已生效或在履行的额度)。 本额度公司及合并报表范围内的子公司均可使用。在不超过总额度范围内，最终 以银行实际审批的额度为准，具体融资金额视公司及子公司实际需求确定。 2、有效期：上述额度有效期为自本次董事会审议通过之日起至 2025 年度综 合授信额度获批通过之日止，期限内，额度可循环使用。 3、业务内容：包括但不限于银行贷款、银行承兑汇票及贴现、商业承兑汇 票贴现、供应链金融、资产池（含票据池）、保理、信用证、贸易融资等综合授 信业务（具体业务品种以相关金融机构审批意见为准）。 4、授权情况：授权 ...

葵花药业集团股份有限公司 2、组织形式：特殊普通合伙企业 3、成立日期：2011 年 01 月 24 日。我国会计泰斗潘序伦博士于 1927 年在 上海创建，1986 年复办，2010 年成为全国首家完成改制的特殊普通合伙制会计 师事务所。立信是国际会计网络 BD0 的成员所，长期从事证券服务业务，新证券 法实施前具有证券、期货业务许可证，具有 H 股审计资格，并已向美国公众公司 会计监督委员会 PCAOB）注册登记。 4、注册地址：上海市 5、首席合伙人：朱建弟先生 董事会审计委员会对会计师事务所 2023 年度履职情况评估及履行监督职责情况的报告 根据《 中华人民共和国公司法》、 中华人民共和国证券法》、 上市公司治理 准则》、 国有企业、上市公司选聘会计师事务所管理办法》、 深圳证券交易所上 市公司自律监管指引第 1 号——主板上市公司规范运作》和本公司 公司章程》 等之规定和要求，葵花药业集团股份有限公司《 以下简称"公司"或《"本公司"） 董事会审计委员会本着勤勉尽责的原则，恪尽职守，认真履职。现将审计委员会 对公司 2023 年度年审会计师事务所 2023 年度履职评估及履行监督职责的情况 报告如 ...

葵花药业集团股份有限公司 证券代码：002737 证券简称：葵花药业 公告编号：2024-003 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、认购基金事项概述 关于参与认购基金份额的进展公告 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）于2022年4 月12日披露《关于参与认购基金份额的公告》，公司决定使用自有资金2,000万 元人民币参与认购宁波梅山保税港区华盖利晟股权投资合伙企业（有限合伙）（以 下简称"华盖利晟"）的有限合伙份额，华盖利晟认购首都大健康产业（北京） 基金（有限合伙）（以下简称"主基金"）基金份额。上述事项的具体内容详见 2022年4月12日刊登于《证券时报》、《中国证券报》、巨潮资讯网 （www.cninfo.com.cn ）的相关公告。 二、进展情况 5、出资额：32,101.00 万元整 为进一步专注主业、深耕医药健康领域，经协商，本公司对华盖利晟的投资 份额由人民币2,000万元调减至人民币1,000万元，并据此调整合伙协议。本次认 购基金份额调整事项决策权限在公司管理层，无需提交董事会/股东大会审议。 本次参与 ...

证券代码：002737 证券简称：葵花药业 公告编号：2024-002 葵花药业集团股份有限公司 关于公司控股股东股份解除质押公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）于近日接到 公司控股股东葵花集团有限公司（以下简称"葵花集团"）函告,获悉葵花集团 所持有的本公司部分股份于近日办理了解除质押业务，具体事项如下： 一、本次解除质押基本情况 | 股东名称 | 持股数量 | 持股 | 累计质 | 占其所 | 占公司 | 已质押股份情况 已质押 | | 未质押股份情况 未质押 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | （股） | 比例 | 押数量 | 持股份 | 总股本 | 股份限 | 占已质 | 股份限 | 占未质 | | | | | （股） | 比例 | 比例 | 售和冻 | 押股份 | 售和冻 | 押股份 | | | | | | | | 结数量 | 比例 | 结数量 | 比例 | | | | | ...

| --- | --- | --- | |-------|--------------------------------------------------------------------|-------| | | | 目 录 | | | 一、品牌 OTC 稳中有进，新管理及带领公司导创佳绩 . | | | | 1.1 新管理层带领公司再创佳绩，成人&儿童药两大知名品牌家喻户晓… | | | | 1.2 公司实际控制人为关彦成先生,员工激励持续换发企业活力 | | | | 1.3 降本增效持续推动净利率提升，品牌 OTC 议价力赋予公司稳健现金流… | | | | 二、"品牌+控情"进就维合誉销能力，"买皮联研代"打造梯队产品群 | | | | 2.1 手提千余个药品文号，打造郴队式品牌产品集群… | | | | 2.2 两大核心品牌引领，孵化多个子品牌，构建品牌生态系统… | | | | 2.3 控销模式造就独特竞争壁垒, 推动产品排队持续放董增长 | | | | 2.4 公司品牌形象深入人心，未来有望保持客高于行业增速增长 | | | | 三、业务拆分+星利领测+估值+分虹. | | | | 3.1 ...

证券代码：002737 证券简称：葵花药业 公告编号：2024- 001 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）全资子公司 哈尔滨葵花药业有限公司（以下简称"哈葵花"）于近日收到国家药品监督管理 局下发的关于盐酸非索非那定口服混悬液申请注册上市许可的《受理通知书》， 现将有关情况公告如下： 一、 药物的基本情况 （1）季节性过敏性鼻炎 适用于缓解成人和 2 岁及 2 岁以上儿童的季节性过敏性鼻炎相关的症状， 如打喷嚏，流鼻涕，鼻、上颚、咽喉发痒，眼睛发痒、潮湿、发红。 （2） 慢性特发性荨麻疹 1 葵花药业集团股份有限公司 关于盐酸非索非那定口服混悬液获得上市许可受理的公告 适用于治疗成人和 6 个月及 6 个月以上儿童的慢性特发性荨麻疹的皮肤症 状，能够减轻瘙痒和风团数量。 二、风险提示 上述药品在获国家药品监督管理局注册上市许可申请受理后，将转入国家药 品监督管理局药品审评中心进行审评审批，鉴于药品审评周期长、环节多，期间 可能受不确定性因素影响，具体完成时间、审批结果存在不确定性。提醒广大 ...